Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789256 · ClinicalTrials.gov registry record · NA
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
A NA study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT00789256 is a NA study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 26 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00789256, a NA study of Myelodysplastic Syndromes and Acute Myelogenous Leukemia, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Bortezomib
- DRUG Melphalan and bortezomib
Study Locations (2)
Florida
- Integrated Community Oncology Network - Jacksonville
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789256
The ClinicalTrials.gov registry entry for NCT00789256 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (91% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 3 interventions - of which Melphalan is the first listed.
NCT00789256 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00789256 about?
NCT00789256 is a clinical study titled "Low Dose Melphalan and Bortezomib for AML and High-Risk MDS". The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).
What is the current status of trial NCT00789256?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2004-09. Estimated completion is 2008-12.
What conditions does trial NCT00789256 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT00789256?
The interventions under investigation include: Melphalan (DRUG), Bortezomib (DRUG), Melphalan and bortezomib (DRUG).
Who is sponsoring clinical trial NCT00789256?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00789256 being conducted?
This trial has 2 study locations across Florida, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Telehealth Advance Care Planning Intervention
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Home Blood Transfusions
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
RECRUITING · NA
-
Mosaic Trial for Stem Cell Transplant Recipients
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.